OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - ELI LILLY & CO | Market Closed - Deutsche Boerse AG 20:39:55 08/05/2024 BST | ||
| 62.27 EUR | -0.18% |
|
| Current month | -1.13% | ||
| 1 month | +0.74% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 62.27 | -0.18% | 0 |
| 07/05/24 | 62.38 | +2.03% | 0 |
| 06/05/24 | 61.14 | +4.46% | 0 |
| 03/05/24 | 58.53 | -3.38% | 0 |
| 02/05/24 | 60.58 | -3.81% | 0 |
Delayed Quote Deutsche Boerse AG
Last update May 08, 2024 at 08:39 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD0T7G |
| ISIN | DE000SD0T7G1 |
| Date issued | 28/10/2020 |
| Strike | 106.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.97 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 63.74 € |
|---|---|
| Lowest since issue | 3.42 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
775
USD
Average target price
848.3
USD
Spread / Average Target
+9.46%
- Stock Market
- Certificates
- Certificat
